Affecting approximately 100.000 persons in the Netherlands alone, the prevalence of IBD is rising. Its cause is multifactorial, involving a complex interplay between host genetics, environmental factors including the diet and dysregulated immune responses towards the gut microbiome.
Patients are eligible for participation if:
Patients with primary sclerosing cholangitis.
Please visit the UMCG Research Data Catalogue for more detailed information on our data and samples.
The following data is included:
Please visit Centrum voor Chronische Darmziekten for more information about patient participation (in Dutch).
IBD is one of the immune mediated inflammatory diseases (IMID) that is showing a rising incidence worldwide. Therefore, exploration of (modifiable) factors involved in disease development as well as its course is crucial for future preventative strategies. Also, research focused on prediction of medication efficacy instead of the current trial-and-error treatment strategy, will potentially lead to better disease management (i.e. shorter time to remission) and decrease in health care costs.
University Medical Center Groningen (UMCG)
Parelsnoer Inflammatory Bowel Diseases (PSI-IBD)
PO Box 30.001
9700 RB Groningen
The Netherlands
Visiting address
University Medical Center Groningen (UMCG)
Department of Gastroenterology and Hepatology
Hanzeplein 1
9713 GZ Groningen
More information visite our website
